This supplementary material is structured as follows. In Sections S1 and S2, we present detailed information about the full conditional posterior distributions of the iBAG model and the associated posterior sampling schemes. In Section S3, we present the additional simulation results to supplement those presented in the main manuscript. In Section S4, we describe the pre-processing procedures for The Cancer Genome Atlas (TCGA) glioblastoma (GBM) study, and we present some additional results obtained by the iBAG model.
..,K Figure S1 : Directed acyclic graph representation of the iBAG model for k = 1, . . . , K. And similarly, the prior for the typeM effect for the kth gene ([γM k |λM , σ]) can be rewritten as:
The full conditional distributions for the parameters in the mechanistic model can be expressed as follows.
• [ω j0,k0 |others ], the methylation level of the j 0 th methylation effect on the mRNA level of the k 0 th gene:
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k0 m j0 m j0 + 10 −6 ) −1 , for k 0 = 1, . . . , K, and m j0 within the promoter of the k 0 th gene, where
• [σ 2 k0 |others], the random error modeling the part of the expression of the k 0 th gene that is not explained by methylation:
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The full conditional distributions for the shrinkage parameters can be expressed as follows.
• [(λ M ) 2 | others], the common shrinkage parameter for the gene expression effects modulated by methylation:
• [(τM k ) −2 = ηM k | others], the common shrinkage parameter for the gene expression effects modulated by methylation:
Hence, the posterior samples for the parameters in the iBAG model for continuous responses can be drawn by Gibbs sampling.
S2: Sampling schemes for the iBAG model for discrete/survival responses
In Section 2.4 of the main article, we introduced a continuous latent variable Z as a data augmentation step for our MCMC schemes for discrete and survival responses. For a binary response variable, the relationship between Z and the response variable Y can be expressed as
For a right-censored response variable, the relationship between Z and the response variable Y can be expressed as log(t n ) = Z n if δ n = 1
Conditionally on Z, iBAG models for both discrete and right-censored responses are the same as that for continuous responses.
The drawing scheme for parameters of the iBAG model with binary or censored outcomes has the following steps:
1) Update (γ M , γM , Ω) using Gibbs sampling.
2) Update the variance for the random error term (σ, σ 1 , . . . , σ K )|(γ M , γM , Ω), using Gibbs sampling.
3) Update Z according to equation (S2) if patient clinical outcomes are binary or equation (S3) if patient clinical outcomes are censored.
S3: Additional simulation results

S3.1: ROC analysis
In Section 4 of the main paper, we generate 12 different scenarios based on different combinations of total number of gene expression features, and the correlations between methylation and gene expression features. We fit four models, iBAG unified , iBAG 2-stage , single gene (SG), and non-integrative (nonINT) model, for all the simulated datasets. In this section, we show the receiver operating characteristic (ROC) curves in identifying the true effects of gene expressions and calculate the areas under these ROC curves (AUCs) for all 12 simulated scenarios in Figures S2.1 to S2.3. Figure   S2 .1 summarizes the true positive rate (TPR) versus the false positive rate (FPR) for discovering genes with only type M effects (effects modulated only by methylation). Figure S2 .2 summarizes the TPR versus the FPR for discovering genes with only typeM effects (effects modulated only by other mechanisms). Figure S2 .3 summarizes the TPR versus the FPR for discovering genes with type M +M effects (effects modulated by both methylation and the other mechanisms). The different line colors in these figures represent different models; different line types represent varying correlations between gene expression and methylation features (see the figure legends). The AUCs of the corresponding ROC curves are enclosed within parentheses in the legends.
In Figure S2 .1, since only the first 200 genes in the gene expression dataset are modulated by methylation, and genes 181 to 200 have effects modulated by both methylation and other mechanisms, we include only the first 180 genes when we calculate the TPR and the FPR. As expected, the nonINT model performs the worst of all three models, followed by the iBAG 2-stage model and the SG model. The proposed iBAG unified model performs the best of all three models.
All of the genes are included when we calculated the TPR and the FPR shown in Figure S2 .2, except genes 1 to 20, which have effects modulated by only methylation, and genes 181 to 200, which have effects modulated by both methylation and other mechanisms. This figure shows that the SG model performs the worst in discovering the genes with typeM effects. The nonINT model performs slightly better than the iBAG 2-stage model in discovering this group of genes. The proposed iBAG unified model performs the best of all three models.
All of the genes are included when we calculate the TPR and the FPR shown in Figure S2 .3, except genes 1 to 20, which have effects modulated only by methylation, and genes 201 to 220, which have effects modulated only by other mechanisms. This figure shows that the SG model performs the worst in discovering the genes with effects modulated by both methylation and other mechanisms.
The iBAG 2-stage model performs as well as the nonINT model in discovering the genes in this group of genes. The proposed iBAG unified model performs the best of all three models.
S3.2: Model performance and consistency
For the situation that best mimics our real data scenario (K = 1000 and ρ = −0.6), we ranked the performance of four different models in identifying different sets of genes based on their AUC values. Table S1 shows that our proposed iBAG unified model performs the best of all three models in discovering all three group of genes. The iBAG 2-stage model ranks second except for in one case.
The SG model and the nonINT model have the worst performances.
In addition, we evaluate the consistency of the iBAG unified model, both in terms of model selection and estimation. We generate 100 datasets for the simulation scenario in which the total number of genes (K) is 1000 and the methylation-gene expression correlation is equal to −0.6. To evaluate the consistency of the iBAG unified model in variable (gene) selection, we summarize the posterior probabilities for the genes with nonzero and zero effects using barplots with standard errors across the 100 datasets (see panels A and B in Figure S3 ). In addition, we calculate the AUCs for identifying genes with nonzero effects for each dataset. The barplots of the AUCs from 100 datasets are shown Figure S3 , panel C. Panels A and B show that for the 100 simulated datasets, the genes with nonzero gene expression effects consistently have higher posterior probabilities than the genes with zero gene expression effects modulated both by methylation (γ M ) and other genomic changes (γM ).
This leads to higher AUCs in selecting genes that are important (with nonzero effects) to clinical outcomes. As shown in panel C, the AUCs based on the iBAG unified model are about 0.8, with very small standard errors in identifying both gene effects modulated by methylation and gene effects modulated by other genomic changes. Hence, from Figure S3 , we conclude that the iBAG unified model demonstrates good (empirical) consistency in selecting relevant variable (genes).
The mean biases for some of the regression and variance parameters over the 100 datasets, along with the standard errors, are summarized in Table S2 . We observe some bias in our parameter estimates, with the bias being slightly higher for true (non-zero) effects than for zero effects. Although we observe good (empirical) consistency in our model selection, biases are observed in our parameter estimates are for two reasons. First, our construction of the double exponential prior has a single (global) shrinkage parameter for all the regression coefficients (large and small), which may tend to over-shrink large effects and under-shrink the small effects. This problem can be alleviated by assuming adaptive versions of the lasso prior such as normal-gamma-based priors Brown, 2010, 2011) , which allows for additional flexibility, but at the cost of additional computation. Second, the consistency of the estimations of regression coefficients in the lasso model has been proven by Knight and Fu (2000) as the sample size goes to infinity. However, in our case, since the sample size (number of patients, N ) is much smaller than the total number of predictors (total number of genes, K), this may lead to bias in our parameter estimates. Table S2 : Mean biases for parameters in the iBAG unified model, estimated from 100 simulation datasets (total number of genes: K = 1000, methylation-gene expression correlation: In this section, we explain the pre-preprocessing steps for the TCGA GBM dataset before applying the iBAG unified model, and provide additional analysis results.
S4.1 Pre-processing procedures
Methylation data: The DNA methylation information is obtained by using the Illumina Human methylation 27 BeadChip. Level 3 data are downloaded directly from the TCGA website (http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp). The downloaded data contain the measures of normalized unmethylated (U ) and methylated (M ) levels for 27,578 highly informative CpG sites per sample at single-nucleotide resolution. We calculate the beta values for each site, which equal
The beta value is a number between zero and one that measures the percentage of DNA methylation on a site. Next, we remove the methylation sites from our analysis if fewer than 5% or more than 95% of samples have beta values less than 0.5. The purpose of this step is to ensure that the beta values for the selected probes vary by patient. After this step, we have 6890 sites left.
Gene expression data: The gene expression data are obtained by using Affymetrix Human Genome U133A Array, which consists of the expression level of 12,000 well-characterized human genes. Level 2 data are downloaded from the TCGA website. The data are normalized globally using BrainArray CDF and the RMA normalization method. This normalization process generates one unique expression level for each human gene. We then remove the underexpressed genes according to the following rule: Patients are divided into a short survival group and a long survival group using 2 years as the cutoff point. A gene is defined to be underexpressed and removed if the means of the normalized expression for both groups are less than 5. This leaves us with 7785 genes.
Annotate methylation features to genes: For each of the 7785 genes, we can obtain the per-centage of methylation for all the sites within its promoter using the following steps. 
S4.2 Additional analysis results
As explained in the main paper, we fit three models to the processed GBM dataset. The first model is the nonINT model, with only gene expression information as explanatory variables. The second model is the additive (ADD) model, with both gene expression and methylation information as explanatory variables and assuming their effects on patients' survival times are additive. The third model is the iBAG unified model for censored outcomes, which integrates both gene expression and methylation information in a hierarchical manner.
In Table S3 , we provide a list of 136 genes that are identified as significantly modulated by at least one methylation feature using the iBAG unified model, based on 95% credible intervals. In Tables S4.1 and S4 .2, we provide a summary of the number of significant prognostic genes for the iBAG unified and ADD models, respectively, along with their type of effects. In addition, we use a Venn diagram to compare the gene lists derived by the iBAG unified and ADD models ( Figure S4 ).
We observe that 59 out of 78 genes with significant gene expression effects obtained by the ADD model overlap with the genes with nonzero typeM effects obtained by the iBAG unified model, and affect survival time in the same direction (both are positive or negative). There are 12 common genes identified from the comparison of genes with significant methylation effects (using the ADD model) to genes with nonzero type M effects (effects modulated by methylation).
Of the 22 genes identified by effects modulated by methylation, 14 are negatively associated with survival, while 8 genes are positively associated with survival. Functional analysis with the database for annotation, visualization and integrated discovery (DAVID, Dennis et al., 2003) for these 22 genes are shown in Table S5 .1 for genes negatively associated with survival, and in Table S5 .2 for genes positively associated with survival. Table S5 .1: Functional analysis results using the database for annotation, visualization and integrated discovery genes (DAVID, Dennis et al., 2003) for the 18 genes with significant NEGATIVE methylation-modulated effects, as identified by the iBAG unified model.
Reading left to right: the first column shows the different categories of gene ontology clusters; the second column shows the gene ontology terms with which these genes are associated; the third and fourth columns show the number and the percentage of genes within this gene ontology cluster; the fifth column shows the p-value for the enrichment of the gene ontology cluster; the last column shows the Entrez GeneID for each of the genes belonging to this cluster. (Gelman and Rubin, 1992) 
